论文部分内容阅读
目的:观察进展期胃癌D2根治术后行同步放化疗的疗效和不良反应。方法:选择D2根治术后进展期胃癌60例,随机分为观察组和对照组各30例。对照组采用奥沙利铂+替吉奥进行化疗;观察组在奥沙利铂+替吉奥化疗的基础上,从第2周期化疗开始进行同步放疗。结果:观察组术后1年、2年生存率均显著高于对照组(P<0.05);术后6个月、1年、2年复发率均显著低于对照组(P<0.05)。观察组Ⅰ、Ⅱ级消化道不良反应发生率显著高于对照组(P<0.05),其他不良反应两组差异不显著(P>0.05)。结论:进展期胃癌患者D2根治术后接受替吉奥联合奥沙利铂方案化疗同步放射治疗,可显著降低术后复发率,提高生存率;Ⅰ、Ⅱ级消化道反应较单纯化疗增加,但患者基本可耐受。
Objective: To observe the curative effect and side effects of concurrent chemoradiotherapy after radical gastrectomy for advanced gastric cancer. Methods: Sixty cases of advanced gastric cancer after D2 radical resection were randomly divided into observation group and control group with 30 cases each. The control group was treated with oxaliplatin + tioguanide. The observation group was treated with oxaliplatin plus tirofiban, and the concurrent radiotherapy was started from the second cycle of chemotherapy. Results: The 1-year and 2-year survival rates of the observation group were significantly higher than those of the control group (P <0.05). The recurrence rates at 6 months, 1 year and 2 years after operation were significantly lower than those in the control group (P <0.05). The incidence of adverse reactions in the observation group Ⅰ and Ⅱ digestive tract was significantly higher than that of the control group (P <0.05). There was no significant difference in other adverse reactions between the two groups (P> 0.05). Conclusions: Radiotherapy of patients with advanced gastric cancer after radical resection of D2 with oxagine plus oxaliplatin chemotherapy can significantly reduce the recurrence rate and improve the survival rate. The grade Ⅰ and Ⅱ gastrointestinal reactions increase compared with chemotherapy alone, Patients are basically tolerable.